mutant APOBEC3G (NCI)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug Namemutant APOBEC3G (NCI)
Drug Alias Namemutant apolipoprotein B mRNA editing enzyme-catalytic polypeptide-like 3G (NCI)
ClassificationBiologics > Protein drugs > Recombinant protein
Mechanisms of ActionAPOBEC3G deaminase modulators
TargetsAPOBEC3G deaminase
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Institutes Of HealthNational Cancer Institute
Active IndicationsN/A
Inactive IndicationsHIV Infections

Other Information

ATC CodeN/A
Related LinksN/A